Dr. Tehrani is one of Zymeworks' co-founders and currently serves as President and CEO of the company. He has been an integral part of many of the Company's corporate achievements including raising seed and angel financing and overseeing the Company's technical operations and patent filings. Dr. Tehrani holds both Bachelors and Masters of Science degrees in Biochemistry from the University of Massachusetts, and has a Doctoral degree in Microbiology and Immunology from the University of British Columbia. While completing his PhD degree he co-founded the Student Biotechnology Network, for which he received the UBC Faculty of Science Achievement Award for Outstanding Leadership in 2002.
Dr. Tehrani has served on the MITACS Industrial Advisory Board, and BIOTECanada's Industrial and Environmental Committee. Currently, he is a member of the Board of Directors of LifeSciences British Columbia and the Student Biotechnology Network.
Mr. Klompas is Zymeworks' Chief Financial Officer, and brings over 20 years of healthcare and biotechnology experience to Zymeworks' management team. Additionally, in conjunction with the CEO, he manages Zymeworks' corporate growth initiatives including corporate alliances, licensing and partnerships. Prior to joining Zymeworks he worked with KPMG LLP in Canada and the US, most recently with KPMG's Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton NJ, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, Mr. Klompas worked with KPMG's Canadian Biotechnology and Pharmaceuticals practice in the fields of assurance, valuations and taxation. Mr. Klompas is a Chartered Accountant and is a member of the institute of CA's of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia and serves on the faculty advisory board for Biotechnology and Chemistry for Camosun College.
Dr. Dixit is Zymeworks' Chief Technology Officer, responsible for the implementation of novel algorithms and advancement of the ZymeCAD™ platform. Prior to joining Zymeworks, Dr. Dixit was the coordinator of Computational Molecular Biophysics at Weselyan University, Connecticut, USA, where he was instrumental in the development of novel methods for management and mining of high throughput molecular dynamics simulation data. Dr. Dixit obtained his PhD at the Indian Institute of Technology, New Delhi researching methods for computing the binding and interaction energies in protein DNA complexes. Subsequently he was a post doctoral research associate at the Université Henri Poincaré, Nancy, France, working on the development and implementation of highly accurate methods for the prediction of binding energies in drug discovery research.
Mr. Tucker is Zymeworks’ Chief Operating Officer, and brings over twenty years of experience in technology development. Prior to joining Zymeworks, Mr. Tucker was Director of Product Development at PMC-Sierra where he managed major projects utilizing over 100 employees. Previously, Mr. Tucker was Director of Silicon Development at Datum Telegraphic, a Canadian start-up acquired by PMC-Sierra in 2000, and was Senior Manager of Design at Epson R&D. Mr. Tucker holds a Bachelor's degree in Electrical Engineering from the University of Alberta.
Dr. Ng is Zymeworks’ Chief Scientific Officer, and brings over fifteen years of biotechnology and pharmaceutical drug discovery experience to the management team. He oversees Zymeworks’ preclinical development programs and manages the Company’s relationships with its external research partners. Prior to joining Zymeworks he worked with the Myelin Repair Foundation, Amgen, and the Merck Frosst Center for Therapeutic Research. During his nine years at Amgen he served as a Scientific Director and was instrumental in advancing multiple preclinical candidates towards the clinic, as well as managing multiple internal and partnered research initiatives. Dr. Ng holds both Doctoral and Masters degrees in Pharmacology from the University of Toronto as well as a Bachelor of Pharmacy from the University of British Columbia.
Dr. Kaufman-Shaw is Zymeworks’ Vice President, Intellectual Property and Legal Affairs, and brings with her over twenty years of intellectual property management, strategy, and execution experience to the management team. Dr. Kaufman-Shaw is responsible for Zymeworks’ IP portfolio and global patent strategy, as well as supporting therapeutics and platform licensing activities and general legal matters. Prior to joining Zymeworks, Dr. Kaufman-Shaw was a Co-Founder of ImStar Therapeutics Inc. and also served as its Vice President, Intellectual Property and Legal Affairs. She also served as a Vice President at both Sirius Genomics Inc. and QLT Inc. where she was responsible for developing and executing intellectual property strategies. Dr. Kaufman-Shaw is admitted to both the Alberta and British Columbia Bars and holds a Bachelor of Laws (LL.B.) and a doctorate in Biochemistry from the University of Alberta. She is currently serving as a member of the MRM Proteomics Inc. board of directors.